The variety of blood cells decreases with age. Some are lost, while others become dominant, leading to a loss of functional ...

A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments.

Salvia Bioelectronics BV raised $60 million in a series B financing round for its minimally invasive implantable neuromodulation device, Mysalvia therapy, which treats chronic migraine. The funds will ...

GC Genome Corp. priced a Kosdaq offering of 4 million shares at ₩10,500 per share May 27, entailing a gross ₩42 billion (US$30.5 million) raise in early June. The Yongin, South Korea-based genomics ...

Researchers at the University of Michigan designed an optimized viral protein able to boost the antitumor function of T cells. The project stemmed from observations on the particular system employed ...

Progressive multifocal leukoencephalopathy (PML) is a fatal demyelinating disease of the central nervous system caused by lytic infection of oligodendrocytes by pathogenic strains of the JC ...

Researchers have been exploring ways to activate the cGAS/STING pathway in tumors as a way to slow their growth.

Latus Bio Inc. is developing a new gene therapy, LTS-101, for the treatment of neuronal ceroid lipofuscinosis type2 (CLN2), a form of Batten disease characterized by deficiency in the tripeptidyl ...

Individuals with both sickle cell disease (SCD) and sickle cell trait are at higher risk than others of developing renal medullary cancer (RMC), the rarest and deadliest subtype of kidney cancer.

In their efforts to develop next-generation drugs whose structures differ from those of conventional IMiDs, researchers at Fujimoto Pharmaceutical Corp. developed FPFT-2216 through optimization of a ...

Autobahn Therapeutics Inc. has disclosed fatty acid amide (FAAH) cleavable prodrugs acting as sphingosine 1-phosphate S1P1 receptor (S1PR1; EDG1) and/or S1P5 receptor (S1PR5; EDG8) agonists reported ...

In their ongoing search for effective small-molecule inhibitors of focal adhesion kinase (FAK), researchers at Beijing Normal University and collaborators started from a promising lead compound that ...